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Purpose: Precise monitoring of active angiogenesis in neovascular eye diseases such as age-related macular degeneration
(AMD) enables sensitive use of antiangiogenic drugs and reduces adverse side effects. So far, no in vivo imaging methods
are available to specifically label active angiogenesis. Here, we report such a technique using fluorophore-labeled cationic
liposomes (CL) detected with a standard clinical in vivo scanning laser ophthalmoscope (SLO).
Methods: C57Bl/6 mice underwent laser coagulations at day 0 (d0) to induce choroidal neovascularization (CNV).
Liposomes labeled with Oregon green, rhodamine (Rh), or indocyanine green (ICG) were injected into the tail vein at
various time points after laser coagulation, and their fluorescence was observed in vivo 60 min later using an SLO, or
afterwards in choroidal flatmounts or cryosections.
Results: SLO detected accumulated fluorescence only in active CNV lesions with insignificant background noise. The
best signal was obtained with CL-ICG. Choroidal flatmounts and cryosections of the eye confirmed the location of retained
CL in CNV lesions. Neutral liposomes, in contrast, showed no accumulation.
Conclusions: These results establish fluorophore-labeled CL as high affinity markers to selectively stain active CNV.
This novel, non-invasive SLO imaging technique could improve risk assessment and indication for current intraocular
antiangiogenic drugs in neovascular eye diseases, as well as monitor therapeutic outcomes. Labeling of angiogenic vessels
using CL can be of interest not only for functional imaging in ophthalmology but also for other conditions where
localization of active angiogenesis is desirable.
Age-related macular degeneration (AMD) is the leading
cause of blindness in the Western world with a prevalence of
1.5% in the population 40 years or older (data for the United
States). The incidence increases with age, affecting 12% of
people over the age of 80 [1]. The number of patients having
AMD is estimated to double by 2020, due to increased life
expectancy [1]. Therefore, preventing and treating AMD play
crucial roles in an individual patient’s quality of life as well
as for the socioeconomic aspects of a sustainable health-care
system [2,3]. AMD presents in two major forms: the exudative
or  wet  form  is  characterized  by  activation  of  pathologic
subretinal angiogenesis resulting in the formation of choroidal
neovascularization (CNV) while the dry form presents with
degeneration  of  the  choroidal  capillaries  and/or  retinal
pigment epithelium (RPE). The exudative form with active
CNV  formation  usually  represents  a  rapidly  progressive
disease, and patients often develop severe visual impairment
within months if left untreated [2].
Current treatments for wet AMD with angioinhibitory
drugs  such  as  bevacizumab  or  ranibizumab  have
demonstrated  efficient  reduction  of  subretinal  fluid  and
Correspondence  to:  Hansjürgen  T.  Agostini,  University  Eye
Hospital,  University  of  Freiburg,  Killianstr.  5,  79106  Freiburg,
Germany,  Phone:  004976127040010;  email:
hansjuergen.agostini@uniklinik-freiburg.de
maintenance of visual acuity [4]. Many other antiangiogenic
agents are currently under investigation or in clinical trials.
However,  long-term  repeated  intraocular  injections  are
required with all current drugs to maintain visual acuity. But
accurate use of the treatments is critical to improve patient
safety.  Not  only  specific  and  quantitative  detection  of
angiogenic activity in AMD is crucial to precisely define the
need and time for intraocular reinjections of angioinhibitory
drugs [5,6], but also sensitive diagnostic measures are needed
to detect early stages of exudative AMD to initiate treatment
at the first sign of angiogenic activation [7].
The standard imaging method for patients with wet AMD
to  date  is  fundus  fluorescence  angiography  (FFA).  FFA
provides information about vessel perfusion and leakage, but
not direct evidence of the proliferative activity of lesions.
Therefore, the interpretation of FFA results to determine the
activity of the lesion depends on individuals’ experience and
subjective opinions. Detecting early onset of non-leaky CNV
lesions is a challenging task using FFA. The interpretation of
FFA results of minimally active CNV can be hampered, for
example, by drusen that absorb fluorescein seen in the late
phase of FFA. Loss of RPE can lead to hyperfluorescence in
the early phase of FFA. In some large eye care centers, optical
coherent tomography (OCT) in the time or spectral domain
modus has thus developed to form one of the cornerstones of
modern macular imaging and is sensitive in measuring retinal
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1045thickness and intra- or subretinal fluid. Combining OCT and
FFA allows precise assessment of retinal thickness, retinal
fluid  accumulation,  and  fluorescein  leakage,  but  neither
method provides direct evidence of the angiogenic activity in
CNV lesions. Nevertheless, FFA and OCT can be potentially
further developed to image cellular and molecular processes
using appropriate tracers and contrast agents.
Cationic liposomes (CL) exhibit high affinity for binding
to sites of active angiogenesis in tumors, inflammation, and
other sites of angiogenesis without extravasation [8]. CL are
rapidly cleared from the circulation by the liver, spleen, and
lung  after  intravenous  injection  [9-11].  They  have  been
evaluated as potential drug-delivery vehicles for angiogenic
tumors in animal models [12-18].
Based on the angiogenic nature of CNV lesions of wet
AMD, we assessed the potential of CL as a delivery system
for fluorophores in functional fundus imaging of active CNV.
We  synthesized  CL  with  stable  conjugation  with  Oregon
Green  488  (OG)  or  indocyanine  green  (ICG),  which  are
detectable in commonly used scanning laser ophthalmoscope
(SLO) systems or fundus cameras used in FFA. The specific
binding and clear detection of fluorophores in the active CNV
lesions in a murine model suggest that our formulations of CL
can be potentially used in patients with AMD to determine
CNV activity precisely.
METHODS
A novel in vivo imaging method for activated angiogenesis
sites  in  CNV  lesions  using  fluorophore-labeled  CL  was
established. OG, a fluorescein derivative with more favorable
fluorescence  properties,  ICG,  and  lissamine-rhodamine  B
(Rh)  were  used  as  fluorescent  labels.  ICG  and  OG  are
detectable with commercially available SLO or other fundus
cameras used in FFA.
Synthesis and analytical characterization of fluorophore-
labeled  cationic  liposomes:  1,2  Dioleoyl-3-
trimethylammonium  propane  (DOTAP)  was  from  Merck
Eprova  (Schaffhausen,  Switzerland),  and  1,2  dioleoyl-sn-
glycero-3-phosphocholine  (DOPC)  and  1,2  dioleoyl-sn-
glycero-3-phosphoethanolamine-N-(lissamine  rhodamine  B
sulfonyl) (Rh-DOPE) for making CL-Rh were from Avanti
Polar Lipids, Inc. (Alabaster, AL). (Oregon Green 488) 1,2
dihexadecanoyl-sn-glycero-3-phosphoethanolamine  (OG-
DHPE) for making CL-OG was obtained from Invitrogen
(Karlsruhe,  Germany).  Indocyanine  green-1,2  di  (cis-9-
octadecenoyl)-sn-glycero-3-phosphoethanolamine  (ICG-
DOPE) for making CL-ICG was synthesized by Molecular
Probes (Invitrogen, Karlsruhe, Germany, custom synthesis).
Liposomes with a total lipid concentration of 10 mM were
prepared  by  the  lipid  film  method  (see  Table  1  for
compositions). To prepare the liposomes, the respective lipids
and lipid-coupled dyes were dissolved in 15 ml chloroform in
a round bottom flask. The mixture was gently warmed to
40 °C, and the solvent was evaporated at reduced pressure in
a rotary evaporator. The resulting lipid film was dried under
vacuum for about 60 min, and then it was resuspended in an
aqueous  solution  containing  10%  trehalose.  The  resulting
suspension of the multilamellar vesicles was extruded (10 ml
Lipex  extruder;  Northern  Lipids  Inc.,  Vancouver,  BC,
Canada) five times through a 0.2 µm polycarbonate membrane
(GE  Osmonics,  Minnetonka,  MN),  yielding  unilamellar
liposomes.  To  prepare  10  ml  of  neutral  liposomes,  0.095
mmol DOPC and 0.005 mmol OG-DHPE were dissolved in
chloroform and treated as described above.
The particle size and size distribution of the liposomal
suspensions  were  analyzed  with  photon  correlation
spectroscopy (Malvern Zetasizer 3000; Malvern Instruments,
Herrenberg, Germany), and the results are listed in Table 1.
The concentration and purity of the liposomal components
were checked with high-performance liquid chromatography
(HPLC)-ultraviolet/visible spectroscopy.
The  fluorescence  properties  of  all  formulations  were
optimized and checked with fluorescence spectroscopy using
a  fluorescence  spectrophotometer  (HORIBA  Jobin  Yvon
GmbH,  Munich,  Germany).  Liposomal  formulations  were
diluted 1:50 (CL-ICG) or 1:2,000 (CL-OG) in trehalose. The
excitation wavelength was set to 805±5 nm (ICG) or 490±5
nm (OG), and the emission was measured at 825±5 nm (ICG)
or 534±5 nm (OG).
Mouse  RPE  was  isolated  from  a  freshly  prepared
posterior  eye  cup  after  the  retina  was  removed  and
appropriately diluted. The absorption spectrum demonstrates
the amount of light absorbed by RPE in different wavelengths
and thus estimates the reduction in fluorescence emitted by
TABLE 1. SUMMARY OF LIPOSOMAL FORMULATIONS.
    Composition
Formulation Particle size/polydispersity index DOTAP DOPC lipid coupled dye
CL-OG 133 nm / 0.163 6 mM 3.5 mM 0.5 mM
CL-Rh 158 nm / 0.183 5 mM 4.5 mM 0.5 mM
CL-ICG 162 nm / 0.236 6 mM 3.5 mM 0.1 mM
neutral liposomes with OG 178 nm / 0.287 0 mM 9.5 mM 0.5 mM
Abbreviations: CL represents cationic liposomes, OG represents oregon green, ICG represents indocyanine green, DOTAP
represents 1,2 Dioleoyl-3-trimethylammonium propane, and DOPC represents 1,2 dioleoyl-sn-glycero-3-phosphocholine.
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in vivo.
Laser-induced choroidal neovascularization model: All
animal procedures adhered to the animal care guidelines of
the Institute for Laboratory Animal Research (Guide for the
Care and Use of Laboratory Animals) in accordance with the
Association  for  Research  in  Vision  and  Ophthalmology
Statement for the Use of Animals in Ophthalmic and Vision
Research  and  were  approved  by  the  local  animal  welfare
committee.
The laser-induced CNV model in mice was performed as
previously described [19]. Briefly, C57BL/6J mice (Charles
River Laboratories, Hamburg, Germany) were anesthetized
with an intraperitoneal injection of a ketamine (100 mg/kg)
and  xylazine  (5  mg/kg)  mixture.  Then  0.5%  tropicamide
(Pharma Stulln, Stulln, Germany) and 0.5% phenylephrine
(Ursapharm, Saarbrücken, Germany) eye drops were used to
dilate pupils. Three laser spots per eye were induced with an
argon laser (100 ms, 100 μm, and 150 mV, 532 nm, Visulas
532s, Carl Zeiss Meditec AG, Jena, Germany). At least three
mice were used per time point and treatment.
In vivo imaging with scanning laser ophthalmoscope:
Fluorophore-labeled liposomes were injected into the tail vein
(10 mM, 150 μl per mouse). Mice were anesthesized, and the
pupils dilated as described above for CNV induction by laser.
CNV were localized in the infrared mode of a digital SLO
(HRA1,  Heidelberg  Engineering,  Heidelberg,  Germany).
Fundus images were taken with filter sets for fluorescein (488
nm excitation, 530 nm emission) and ICG (795 nm excitation,
830 nm emission). Images were taken before and at different
time  points  after  intravenous  injections  of  liposomal
formulations and analyzed with ImageJ. The fluorescence
intensity of a CNV (IL) was calculated by selecting a region
of interest covering the laser CNV and dividing the sum of the
intensity values of each pixel in that area by the number of the
pixels. In the same way, background fluorescence (IB) was
averaged from three areas of identical size and shape as the
CNV area that were selected in close proximity to the CNV.
An accumulation index was defined as IL divided by IB. Values
were  tested  for  statistical  significance  with  ANOVA,  and
differences were assumed to be significant when p<0.05.
Sclerochoroidal  flatmounts  and  microscopy:
Immediately after the in vivo SLO images were taken, eyes
were fixed in 4% formalin buffered with PBS (137 mM NaCl,
2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4). After the
anterior eye part and the retina were removed, the sclera and
choroid complex including the RPE was flatmounted and
examined  with  epifluorescence  microscopy  with  480  nm
excitation  and  510  nm  emission  filters  without  additional
staining. Since ICG signals are detectable only in the infrared
channel, which is unavailable in microscopes, only CL-OG
injected  eyes  were  included.  Images  were  taken,  and  the
selectivity in CNV lesions was quantified in the same way as
in  the  SLO  images.  Three  control  areas  were  selected  in
healthy RPE outside the CNV area.
Histological  localization  of  cationic  liposome  and
fluorescein isothiocyanate-lectin: Mice with L-CNV received
an intravenous application of cationic liposomes labeled with
rhodamine (CL-Rh) at d5 or d14 after laser coagulation (4 µl/
g). The liposomes were allowed to circulate for 60 min before
the animals received 100 µl fluorescein isothiocyanate (FITC)
lectin (2 mg/ml, Vector Labs, Burlingame, CA) intravenously.
After  5  min,  the  animals  were  perfused  with  1%
paraformaldehyde.  Eyes  were  removed  and  embedded  in
optimum control temperature medium (TissueTek, Sakura,
Japan) and quick-frozen in a Leica cryostat (Leica, Wetzlar,
Germany). Then 50 µm sections were cut, dried for 30 min at
room temperature, fixed in 4% buffered formalin, and stained
with 10 µM ToPro-3 (Invitrogen, Karlsruhe, Germany) for 1
min  at  room  temperature.  After  being  washed  with  PBS,
sections were mounted in Dako faramount aqueous (Dako,
Hamburg,  Germany),  left  to  dry  for  60  min  at  room
temperature in the dark, and analyzed with a Leica TCS SP2
confocal  microscope  (Leica,  Heidelberg,  Germany)  at
excitation wavelengths of 488 nm, 543 nm, and 633 nm.
RESULTS
Optimization  of  fluorophore-labeled  liposomes:  The
fluorophores OG, ICG, and Rh were stably linked to CL as
they  were  covalently  bound  to  phospholipids.  This  was
confirmed  with  high-performance  liquid  chromatography
analysis that did not detect any unbound fluorophore at any
time during the study. Fluorescence intensity was optimal at
1  mol%  ICG  and  5  mol%  OG  in  total  liposomes  due  to
intraliposomal quenching at higher fluorophore ratios (Figure
1).  The  inset  in  Figure  1  shows  the  respective  molecular
structure; OG differs from fluorescein only by having two F
atoms at the aromatic ring system. In both structures, “R”
indicates  where  the  linker  to  the  lipid  moiety  has  been
attached.  Quenching  of  Rh  was  similar  to  OG  in  CL.
Therefore, Rh was also used at a concentration of 5 mol%.
In vivo short-term kinetics of fluorophore-labeled liposomes
(scanning laser ophthalmoscope imaging): The distribution
of CL labeled with ICG or OG in the fundus was followed by
SLO  after  intravenous  injection.  Figure  2  shows
representative images at various time points after application
of labeled CL-ICG or CL-OG 14 days after laser coagulation.
No specific signal was detected before CL-ICG or CL-OG was
injected. Circulation of CL formulations in the blood plasma
was faintly visible for 2–3 min after application based on the
respective fluorescence signal (Figure 2B). After that, fast
accumulation of fluorescence at the CNV site was observed.
Typically, the signal due to CL-OG was visible between 20
and  120  min  after  application.  The  CL-ICG  signal  was
stronger and therefore was visible as early as 5 min after
application and was observed for several hours, in some cases
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observed between 30 and 90 min so that a measuring time
point of 60 min after injection was chosen in the following
experiments. CL-ICG resulted in a more intense and precise
image compared to CL-OG (Figure 2C). In contrast, neutral
liposomes did not accumulate at the laser site but remained
much  longer  in  circulation  (Figure  3)  similar  to  ICG  or
fluorescein in angiography.
Kinetics of choroidal neovascularization formation detected
with scanning laser ophthalmoscope: CL-OG, CL-ICG, and
neutral  liposomes  labeled  with  OG  were  intravenously
applied to mice on various days after laser coagulation. SLO
images were recorded 60 min after injection. The CL-ICG
yielded a clear signal five days after laser treatment. Both CL
formulations showed a significant enrichment at the CNV site
at d10 and d14 compared to neutral liposomes (Figure 3). The
highest value was reached by CL-ICG at d14, where a 3.6-fold
accumulation in the CNV was found. The CL-OG showed a
weaker signal than CL-ICG probably because of absorption
of the OG fluorescence by the RPE (compare Figure 3C). This
shows again that CL-ICG’s signal was superior to that of CL-
OG.
In the d1 CL-ICG image (Figure 3), the central laser burn
was a black hole surrounded by CL-ICG signal (accumulation
<1) probably due to activation of endothelial cells through
local inflammation. This hole was gradually filled in with
blood vessels during the course of the study as illustrated in
the CL-ICG images suggesting that the accumulation of CL
correlates with the growth of choroidal neovessels within the
CNV.
The  SLO  images  obtained  with  CL  represented  the
morphology  of  CNV  lesions  well  at  d10  and  d14,  which
appeared not as a homogenous distribution but as hot spots
whose structure resembled blood vessels (Figure 2 and Figure
3). Neutral liposomes showed no accumulation in the CNV
lesions (Figure 3), but remained in the circulation even 60 min
after the intravenous injection similar to ICG or fluorescein in
angiography. This demonstrates that the cationic charge is
important for the accumulation of CL, which depends on the
biologic status of the growing CNV.
Confirmation  of  laser-choroidal  neovascularization
development with flatmount analysis: The choroids of the
mice  that  were  imaged  with  OG-labeled  liposomes  were
flatmounted and investigated with fluorescence microscopy.
Accumulation  indices  were  computed  analogous  to  the
procedure with SLO and are shown in Figure 4B. Similar to
the SLO data in Figure 3B, there was a significantly increased
accumulation  of  CL-OG  compared  to  neutral  liposomes
labeled with OG at d10 and d14 confirming that CL bound
specifically to the CNV site. The CL-OG signal was much
weaker  at  d1  and  d5,  accompanied  by  homogeneous
background  staining.  Flatmounts  from  mice  treated  with
neutral  liposomes  showed  background  staining  as  well.
Background staining is typically derived from tissues such as
muscle showing autofluorescence at the wavelength used for
detecting OG.
Histological localization of cationic liposomes: To detect CL
in histological sections, CL-Rh was applied intravenously,
and  blood  vessels  were  labeled  with  fluorescein  cyanate
(FITC) lectin. Figure 5 shows representative images of laser-
CNV at d5 and d14 after laser coagulation. The images show
a well defined vessel structure in the retina and in the choroid.
Staining with ToPro-3 allowed the nuclear layers of the retina
that were deformed at the laser site to be identified. CL were
exclusively found at the laser site. However, CL were not
confined to the vessels but showed some spotty distribution
Figure 1. Cationic liposomes (CL) formulations labeled with indocyanine green (ICG) or Oregon green (OG) were internally quenched.
Liposomes  composed  of  60  mol%  1,2  dioleoyl-3-trimethylammonium  propane  (DOTAP),  40  -  x  mol%  1,2  dioleoyl-sn-glycero-3-
phosphocholine (DOPC), and x mol% ICG-DOPE or OG-DOPE were prepared and diluted 1:50 (CL-ICG) or 1:2,000 (CL-OG). Intraliposomal
quenching reduces the fluorescence in the liposomal membrane at concentrations of more than 0.5 mol% ICG or 5 mol% OG. The fluorescence
signal of ICG is ten times lower than that of OG if the different dilutions are taken into account.
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non-specific  binding  of  CL  to  resting  blood  vessels,  to
photoreceptors, or to other structures. The amount of CNV
labeled with CL-Rh increased from d5 to d14 confirming the
results from the SLO and flatmount analysis.
DISCUSSION
The visualization of vascular cells involved in angiogenesis
helps to determine the activity of a pathological process and
to monitor the therapeutic success of angioinhibitory therapy,
for example, in AMD, a disease affecting millions of people
worldwide (1.75 million in the US [1]). The data presented
here show that CL can be labeled with different diagnostic
dyes, accumulate specifically at the site of experimentally
induced choroidal neovascularization, and are detected with
standard clinical scanning laser ophthalmoscopy in a CNV
mouse model. Although angiography with fluorescein or ICG
is based primarily on extravasation due to leaky blood vessels,
imaging with CL allows sites with active angioproliferation
to be visualized and could therefore prove to be a crucial step
toward functional imaging of angiogenesis in ophthalmology.
The fluorescent dyes fluorescein and ICG are routinely
used in fundus fluorescence angiography using SLO. In this
study, CL were labeled with such dyes or their derivatives at
low concentrations (1 and 5 mol% fluorescent dye) that did
not  affect  the  liposome’s  capacity  to  bind  to  active
angiogenesis  sites.  Other  groups  have  also  found  this  in
animal models of cancer and chronic inflammation [8,13] as
well as acute pulmonary inflammation [20]. Compared to
standard  fluorescence  angiography,  the  fluorophore  dose
needed for imaging an angiogenetically active site with CL
was about 0.5% of the fluorescein or ICG dose that would be
applied in angiography.
Figure 2. Kinetics of accumulation of cationic liposomes (CL)- indocyanine green (ICG) or CL-Oregon green (OG) was observed with the
SLO in vivo. A: ICG-CL were injected at d14, and scanning laser ophthalmoscope (SLO) images were recorded in a single choroidal
neovascularization (CNV). While images taken before injection of ICG (0 min) showed no signal, the ICG fluorescence (795 nm excitation,
830 nm emission) became detectable in the CNV after 10 min. Maximal intensity was observed between 30 min and 90 min with a slow
decrease afterwards. Other parts of the fundus were not specifically stained. B: OG-CL were injected at d10, and SLO images were recorded
in a single CNV. This series shows the early signal in the capillaries 2–3 min after injection that disappears quickly [8] while the OG-CL
signal in the CNV is coming up later and for a longer time as shown in A. C: ICG-CL (40%) and CL-OG were mixed and injected at d14, and
SLO images were recorded in a single CNV. Note that the OG signal is somewhat weaker. IR: CNV lesion in infrared modus.
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liposomes (CL)-indocyanine green (ICG), CL-Oregon green (OG), or neutral liposomes labeled with OG were applied intravenously at d1,
d5, d10, or d14 after laser treatment. SLO images were recorded for each laser choroidal neovascularization (CNV) 60 min later. A: One
representative CNV is shown for each time point and for each of the formulations tested. The CL-ICG images are taken from the same CNV
in one mouse, and the corresponding infrared (IR) images are shown for comparison. The other images are taken from different animals.
Although neutral liposomes did not accumulate within the CNV, CL-OG was found from d10 onwards and CL-ICG starting from d5. B: The
ratio of accumulation of liposomes in the CNV to the control area was calculated for each CNV as described in the methods section. The
means and the standard errors of the mean are shown. Values for CL-OG at d10 and d14 and for CL-ICG at d5, d10, and d14 were significantly
higher compared to those of neutral liposomes. Data are means obtained from five mice. Error bars indicate SEM, and asterisks indicate
statistical significance (p<0.05 as compared to d1). C: Absorption spectrum of mouse RPE. After the retina as removed, the RPE was scraped
out, homogenized by pipetting, and diluted in water. Transmission is higher at longer wavelengths. The OG emission was detected at 530 nm
and that of ICG at 830 nm. The murine RPE absorption was about twice as high at 530 nm as at 830 nm. This gives an estimate of the reduction
of fluorescence emitted by fluorophores when they are located behind the RPE in vivo and is one of the reasons why ICG is more suitable for
diagnostics of sub-RPE lesions than OG or fluorescein.
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better for CL-ICG than for CL-OG. In vitro, the fluorescence
emission of the CL-ICG formulation was only about 10% of
that measured for the CL-OG formulation (Figure 1). On the
other hand, the laser intensity at 790 nm was about tenfold
higher than that at 480 nm. In addition, the signal due to OG
was strongly quenched by tissue (especially RPE) and blood
components, so that ICG provided images with higher contrast
than OG.
Previous studies reported the specific binding of cationic
liposomes to angiogenic tumor blood vessels [8,13,14] and to
areas of inflammation [8]. Similar results were found in the
lung where CL-Rh was accumulated at sites stimulated by
lipopolysaccharide [20]. Binding of CL to active angiogenesis
sites has been reported to result in accumulation index values
of about 3 (in vivo imaging) in tumor models [13]. Here,
accumulation index values of about 2–4 are reported based on
SLO imaging. Moreover, the SLO images presented here are
of high quality and contrast as is expected for FFA.
The  positive  charge  of  CL  is  critical  for  preferential
binding by or uptake into angiogenic endothelial cells [13]. In
the present study, the preferential accumulation of different
Figure 4. Accumulation of cationic and neutral liposomes was observed in flatmount preparations. After the scanning laser ophthalmoscope
(SLO) images described in Figure 3 were taken, choroidal-scleral flatmounts were prepared from the mice treated with cationic liposomes
(CL)-Oregon green (OG) or neutral liposomes labeled with OG. Images were taken using fluorescence microscopy. Representative ones are
shown in A. They were evaluated the same way as the SLO images (B). Values for CL-OG at d10 and d14 were significantly higher compared
to those of neutral liposomes. The results confirmed that the kinetics were the same as for the SLO images. Data are means obtained from
five mice. Error bars indicate SEM, and asterisks indicate statistical significance (p<0.05 as compared to d1).
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liposomes  at  active  angiogenesis  sites  in  CNV  was
consistently  found  with  in  vivo  SLO  fundus  imaging,
epifluorescence  microscopy  of  choroidal  flatmounts,  and
fluorescence microcopy of cross-sections of the CNV lesions.
The SLO images presented here (especially those with CL-
ICG) demonstrate that the fluorescence signal was located at
the edge of the lesion and grew from there. The signal was not
uniformly  distributed  over  the  lesional  site  as  typically
observed in fluorescein angiography where leakage is the
underlying mechanism. No extravasal diffusion of the dye was
seen here. Instead, structures resembling blood vessels were
identified. Accumulation of CL was closely associated with
lectin-binding endothelial cells of vessels in cross sections
(Figure 5), and the accumulation was strictly limited within
the laser lesion. Overall, all imaging tools support the view
that CL bind to active angiogenesis sites in the CNV.
The CL-ICG SLO images show some additional staining
surrounding the laser spot. This may be attributed to cells
involved in active angiogenesis similar to those PECAM1
(CD31)  positive  cells  observed  in  rat  CNV  at  d2  [21]
indicating that CL-ICG detects early stages of angiogenesis.
In the laser-induced CNV mouse model, the maximal size
of the CNV membrane is reached 14 days after laser treatment
[19]. A similar time course was reported for monkeys [22]. In
this study, the maximal signal of labeled CL was also observed
Figure 5. Cationic liposomes (CL) were localized in the choroidal neovascularization (CNV). At d5 or d14 after laser coagulation, CL labeled
with rhodamine were applied intravenously. Sixty min later, the mice received FITC-lectin. Then, the eyes were enucleated, and cryosections
were prepared. The CNV is situated between the retina and the choroid at the site where the nucleic layers (blue) of the retina are distorted.
CL were found exclusively in the CNV.
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membrane. Although CL-ICG was already detectable at d5,
CL-OG was found starting at d10.
CL-OG and CL-ICG showed a broad intensity maximum
at least between 30 and 90 min after application. This is a
comfortable time window for thorough clinical evaluation of
a  patient,  even  if  recording  of  both  eyes  is  required.  In
addition, CL-ICG can be applied simultaneously with normal
fluorescein angiography to characterize activation sites and
correlate them with leakage phenomena in the same setting
[23,24].
In  humans,  the  same  CL  loaded  with  paclitaxel
(EndoTAG-1) were used in a phase I study to treat tumors.
They were generally well tolerated [25]. Some toxic effects
such as fatigue or hypersensitivity reactions may be attributed
to the paclitaxel load rather than to the CL. The fluorophores
fluorescein and ICG used in the present study are commonly
used in FFA and well tolerated, too. In addition, no toxic
effects were observed in mice during this study.
In summary, the rationale for imaging using labeled CL
is manifold: this method can help identify initial phases of
choroidal neovascularization, and might serve to monitor the
activity  of  choroidal  angiogenesis,  treatment  success,  or
predict  treatment  outcome.  It  may  help  to  gain  a  better
understanding  of  the  therapeutic  effect  of  antivascular
endothelial growth factor treatment and to predict when the
disease will reappear by gaining information about the CNV
activity in addition to size and leakage. Monitoring angiogenic
activity can be of relevance not only in patients with wet AMD
but also in patients with diabetic retinopathy or retinal vein
occlusion at risk of developing proliferative retinopathy.
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